Income Tax Expense (Benefit) of IOVANCE BIOTHERAPEUTICS, INC. from 31 Dec 2014 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary: IOVANCE BIOTHERAPEUTICS, INC. quarterly and annual Income Tax Expense (Benefit) in USD history and change rate from 31 Dec 2014 to 31 Dec 2025.
IOVANCE BIOTHERAPEUTICS, INC. Income Tax Expense (Benefit) for the quarter ending 31 Dec 2025 was $184,000, a 88% decline year-over-year.
IOVANCE BIOTHERAPEUTICS, INC. Income Tax Expense (Benefit) for the twelve months ending 31 Dec 2025 was $2,071,000, a 27% increase year-over-year.
IOVANCE BIOTHERAPEUTICS, INC. annual Income Tax Expense (Benefit) for 2025 was $2,071,000, a 27% increase from 2024.
IOVANCE BIOTHERAPEUTICS, INC. annual Income Tax Expense (Benefit) for 2024 was $2,828,000, a 19% increase from 2023.
IOVANCE BIOTHERAPEUTICS, INC. annual Income Tax Expense (Benefit) for 2023 was $3,479,000.
Source SEC data: View on sec.gov

Income Tax Expense (Benefit), Trailing 12 Months (USD)

Income Tax Expense (Benefit), Quarterly (USD)

Income Tax Expense (Benefit), YoY Quarterly Change (%)

Income Tax Expense (Benefit), Annual (USD)

Income Tax Expense (Benefit), YoY Annual Change (%)

IOVANCE BIOTHERAPEUTICS, INC. Quarterly Income Tax Expense (Benefit) (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025	$2,071,000	$184,000	-$1,374,000	-88%	01 Oct 2025	31 Dec 2025	10-K	24 Feb 2026	2025	FY
Q3 2025	$697,000	$2,405,000	-$885,000	-58%	01 Jul 2025	30 Sep 2025	10-Q	06 Nov 2025	2025	Q3
Q2 2025	$188,000	$1,988,000	+$3,446,000		01 Apr 2025	30 Jun 2025	10-Q	07 Aug 2025	2025	Q2
Q1 2025	$3,258,000	$1,838,000	-$430,000	-31%	01 Jan 2025	31 Mar 2025	10-Q	08 May 2025	2025	Q1
Q4 2024	$2,828,000	$1,558,000	+$3,317,000		01 Oct 2024	31 Dec 2024	10-K	24 Feb 2026	2025	FY
Q3 2024	$6,145,000	$1,520,000	-$277,000	-22%	01 Jul 2024	30 Sep 2024	10-Q	06 Nov 2025	2025	Q3
Q2 2024	$5,868,000	$1,458,000	-$981,000	-206%	01 Apr 2024	30 Jun 2024	10-Q	07 Aug 2025	2025	Q2
Q1 2024	$4,887,000	$1,408,000	-$1,408,000		01 Jan 2024	31 Mar 2024	10-Q	08 May 2025	2025	Q1
Q4 2023	$3,479,000	$1,759,000			01 Oct 2023	31 Dec 2023	10-K	24 Feb 2026	2025	FY
Q3 2023		$1,243,000			01 Jul 2023	30 Sep 2023	10-Q	07 Nov 2024	2024	Q3
Q2 2023		$477,000			01 Apr 2023	30 Jun 2023	10-Q	08 Aug 2024	2024	Q2
Q1 2023		$0			01 Jan 2023	31 Mar 2023	10-Q	09 May 2024	2024	Q1

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2025	$2,071,000	+$757,000	+27%	01 Jan 2025	31 Dec 2025	10-K	24 Feb 2026	2025	FY
2024	$2,828,000	+$651,000	+19%	01 Jan 2024	31 Dec 2024	10-K	24 Feb 2026	2025	FY
2023	$3,479,000	-$3,479,000		01 Jan 2023	31 Dec 2023	10-K	24 Feb 2026	2025	FY
2022	$0	$0		01 Jan 2022	31 Dec 2022	10-K	27 Feb 2025	2024	FY
2021	$0	$0		01 Jan 2021	31 Dec 2021	10-K	28 Feb 2024	2023	FY
2020	$0	$0		01 Jan 2020	31 Dec 2020	10-K	25 Feb 2021	2020	FY
2019	$0	$0		01 Jan 2019	31 Dec 2019	10-K	25 Feb 2021	2020	FY
2018	$0	$0		01 Jan 2018	31 Dec 2018	10-K	25 Feb 2021	2020	FY
2017	$0	$0		01 Jan 2017	31 Dec 2017	10-K	25 Feb 2020	2019	FY
2016	$0	$0		01 Jan 2016	31 Dec 2016	10-K	28 Feb 2019	2018	FY
2015	$0	$0		01 Jan 2015	31 Dec 2015	10-K	12 Mar 2018	2017	FY
2014	$0			01 Jan 2014	31 Dec 2014	10-K	09 Mar 2017	2016	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.